Rich P, Schein JR, Lubeck D: Onychomycosis: symptoms and quality of life associated with this medical condition [poster]. Presented at a meeting of the American Academy of Dermatology, July 31–August 4, 1998, Chicago..
Lubeck DP, Gause D, Schein JR, et al: A health-related quality of life measure for use in patients with onychomycosis: a validation study. .Qual Life Res8::121. ,1999. .
Hiruma M, Matsushita A, Kobayashi M, et al: One week pulse therapy with itraconazole (200 mg day-1) for onychomycosis: evaluation of treatment results according to patient background. .Mycoses44::87. ,2001. .
Hiruma M, Matsushita A, Kobayashi M, et al: One week pulse therapy with itraconazole (200 mg day-1) for onychomycosis: evaluation of treatment results according to patient background. .Mycoses44::87. ,2001. .11413929)| false
The purpose of this study, which involved two dermatology clinics and two podiatric medical clinics, was to determine whether a difference exists in patient-reported satisfaction and compliance between continuous terbinafine therapy and pulse-dose itraconazole therapy for the treatment of toenail onychomycosis. Patients in this multicenter, open-label, cross-sectional study had previously completed treatment with either oral terbinafine or oral itraconazole for toenail onychomycosis. Patients were interviewed by telephone to assess clinical outcomes, compliance, and satisfaction with treatment; clinical data were collected by medical chart review. Patients reported significantly greater ease and convenience of treatment and higher overall satisfaction with continuous terbinafine therapy compared with pulse-dose itraconazole therapy. (J Am Podiatr Med Assoc 93(5): 373-379, 2003)
Corresponding author: Erin M. Warshaw, MD, Minneapolis Veterans Affairs Medical Center, Dermatology/IIIK, One Veterans Dr, Minneapolis, MN 55417.